KEEP 2.0 Annual Data Report Chapter Five
|
|
- Fay West
- 6 years ago
- Views:
Transcription
1 KEEP 2. Annual Data Report Chapter Five
2 Figure 5.1 percent distribution of KEEP participants with elevated serum creatinine levels, overall & by age 16 Percent of participants All <6 yrs 6 yrs KEEP: n=1,725; excludes participants with missing serum creatinine values; elevated levels: >1.5 mg/dl in men, >1.3 mg/dl in women
3 Figure 5.2 percent distribution of KEEP participants with elevated serum creatinine levels, by race 8 Percent of participants White Black Nat Am Asian Pac Isl Other KEEP: n=1,413; excludes participants with missing serum creatinine values or unknown or missing race; elevated levels: >1.5 mg/dl in men, >1.3 mg/dl in women
4 Figure 5.3 % distribution of KEEP participants with egfr using MDRD & Cockroft-Gault methods, overall & by age & gender 7 Percent of participants MDRD egfr (<6 ml/min/1.73 m 2 ) Cockroft-Gault Creatinine Clearance (<6 ml/min/1.73 m 2 ) All Male Female KEEP: MDRD egfr, n=1,725; CG, n=1,614; excludes participants with missing values
5 Figure 5.4 percent distribution of KEEP Percent of participants participants with egfr using MDRD & Cockroft-Gault methods, by race MDRD egfr (<6 ml/min/1.73 m 2 ) Cockroft-Gault Creatinine Clearance (<6 ml/min/1.73 m 2 ) White Black Nat Am Asian Pac Isl Other KEEP: MDRD egfr, n=1,413; CG, n=1,38; excludes participants with missing values
6 Figure 5.5 % distribution of KEEP participants with egfr using MDRD & Cockroft-Gault methods, by Hispanic ethnicity Percent of participants MDRD egfr (<6 ml/min/1.73 m 2 ) Cockroft-Gault Creatinine Clearance (<6 ml/min/1.73 m 2 ) Non-Hispanic Mexican Puerto Rican Cuban Other Hispanic KEEP: MDRD egfr, n=7,195; CG, n=7,142; excludes participants with missing ethnicity
7 Figure 5.6 percent distribution of KEEP participants with egfr using MDRD & Cockroft-Gault methods, by U.S. region Percent of participants MDRD egfr (<6 ml/min/1.73 m 2 ) Cockroft Gault (CG) Creatinine Clearance (<6 ml/min/1.73 m 2 ) Northeast Midwest South West KEEP: MDRD egfr, n=1,725; CG, n=1,614; excludes participants with missing values
8 Figure 5.7 percent distribution of KEEP participants with CKD, by CKD status 5 Percent of participants All Stage 1 Stage 2 Stage 3 Stage 4-5 CKD stages Stage 1: CCR 9, microalbuminuria =+ Stage 2: CCR 6 89, microalbuminuria = + Stage 3: CCR 3 59 Stage 4: CCR Stage 5: CCR <15 or patient on dialysis KEEP: n=1,651; excludes participants with missing egfr; CKD defined by egfr <6 ml/min/1.73 m 2 (MDRD formula) or presence of microalbuminuria if egfr 6 ml/min/1.73 m 2
9 Figure 5.8 percent distribution of KEEP participants with CKD, by age & gender 7 Percent of participants with CKD Male Female KEEP: n=1,651; excludes participants with missing egfr; CKD defined by egfr <6 ml/min/1.73 m 2 (MDRD formula) or presence of microalbuminuria if egfr 6 ml/min/1.73 m 2
10 Figure 5.9 percent distribution of KEEP participants with CKD, by race & Hispanic ethnicity 5 Percent of participants with CKD White Black Other Hispanic Non-Hispanic KEEP: n=1,343; excludes participants with missing egfr or race; CKD defined by egfr <6 ml/min/1.73 m 2 (MDRD formula) or presence of microalbuminuria if egfr 6 ml/min/1.73 m 2. Race & Hispanic ethnicity are not mutually exclusive.
11 Figure 5.1 percent distribution of KEEP participants with CKD, by BMI 6 Percent of participants with CKD BMI index BMI <18.5: UW: Underweight BMI : N: Normal BMI : OW: Overweight BMI : OB: Obese BMI 4: EO: Extremely Obese UW N OW OB EO KEEP: n=11,122; excludes participants with missing egfr or BMI values; CKD defined by egfr <6 ml/min/1.73 m 2 (MDRD formula) or presence of microalbuminuria if egfr 6 ml/min/1.73 m 2
12 Figure 5.11 percent distribution of KEEP participants with a family history of kidney disease, overall & by gender % participants w/family history of kidney disease All Male Female KEEP: n=1,96 total, 2,77 with a reported family history of kidney disease; excludes participants with missing family history
13 Figure 5.12 percent distribution of KEEP participants with a family history of kidney disease, by race % participants w/family history of kidney disease White Black Nat Am Asian Pac Isl Other KEEP: n=1,637, 2,68 with a reported family history of kidney disease; excludes participants with missing family history or race
14 Figure 5.13 percent distribution of KEEP participants with a family history of kidney disease, by Hispanic ethnicity % participants w/family history of kidney disease Non-Hispanic Mexican Puerto Rican Cuban Other Hispanic KEEP: n=7,356, 1,845 with a reported family history of kidney disease; excludes participants with missing family history or ethnicity
15 Table 5.1 concordance of egfr, BSA-CG creatinine clearance, & gender-specific cut-points for categorizing abnormal kidney function Serum MDRD egfr BSA-CG creatinine clearance creatinine <6 6 All <6 6 All Elevated Not elevated 1,77 9,111 1,188 1,25 9,61 1,86 All 1,61 9,124 1,725 1,342 9,272 1,614 Elevated: men >1.5, women >1.3 mg/dl Not elevated: men 1.5, women 1.3 mg/dl egfr <6 ml/min/1.73 m 2 = moderate reduction in kidney function
16 Table 5.2 blood pressure levels, by stage of CKD, MDRD egfr, & BSA-CG creatinine clearance Systolic (mmhg) Diastolic (mmhg) Interquar. Interquar. Mean Median SD range Mean Median SD range MDRD Stage I Stage II Stage III Stages IV V Missing Cockcroft-Gault Stage I Stage II Stage III Stages IV V Missing CKD stages Stage 1: CCR 9, microalbuminuria =+ Stage 4: CCR Stage 2: CCR 6 89, microalbuminuria = + Stage 5: CCR <15 or patient on dialysis Stage 3: CCR 3 59
17 Figure 5.14 percent distribution of KEEP participants with elevated blood pressure, by CKD stage 1 14/9 mmhg Percent of participants /85 mmhg CKD stages Stage 1: CCR 9, microalbuminuria =+ Stage 2: CCR 6 89, microalbuminuria = + Stage 3: CCR 3 59 Stage 4: CCR Stage 5: CCR <15 or patient on dialysis Stage 1 Stage 2 Stage 3 Stage 4-5 KEEP: n=1,584; excludes participants with missing CKD stage or blood pressure value
18 Percent of participants Figure 5.15 percent distribution of KEEP participants with elevated blood pressure, by CKD stage, anemia, & egfr 14/9 mmhg 13/85 mmhg A NA A NA A NA A NA Stage 1 Stage 2 Stage 3 Stage 4-5 CKD stages Stage 1: CCR 9, microalbuminuria =+ Stage 2: CCR 6 89, microalbuminuria = + Stage 3: CCR 3 59 Stage 4: CCR Stage 5: CCR <15 or patient on dialysis KEEP: n=1,319; excludes participants with missing CKD stage, anemia status, or blood pressure value; anemia defined by NKF-K/DOQI: males: Hgb <12 g/dl; females age >5: Hgb <12 g/dl; females age 5: Hgb <11 A= anemia, NA= no anemia
19 Figure 5.16 percent distribution of KEEP participants with elevated blood pressure, by CKD & smoking status 1 Percent of participants Smoking Used to smoke Never smoked CKD stages Stage 1: CCR 9, microalbuminuria =+ Stage 2: CCR 6 89, microalbuminuria = + Stage 3: CCR 3 59 Stage 4: CCR Stage 5: CCR <15 or patient on dialysis JNC VI hypertension Stage I: systolic or diastolic 9 99 Stage II: systolic or diastolic 1 19 Stage 1 Stage 2 Stage 3 Stage 4-5 Stage III: systolic ³18 or diastolic ³11 KEEP: n=9,94; excludes participants with missing CKD status, blood pressure status, or smoking status. Hypertension based on JNC definition.
H e alth his to r y. Chapter 3 Health history. s29
3 H e alth his to r y My mama died from undetected kidney disease in Oct. 22. It was only after 2 years of being treated for high blood pressure, a blood test [was done] to check on her kidneys. She went
More informationKEEP Summary Figures S40. Am J Kidney Dis. 2012;59(3)(suppl 2):S40-S64
211 Summary Figures S4 Am J Kidney Dis. 212;59(3)(suppl 2):S4-S64 Definitions DATA ANALYSES DIABETES Self-reported diabetes, self reported diabetic retinopathy, receiving medication for diabetes, or elevated
More informationKEEP Summary Figures S32. Am J Kidney Dis. 2011;57(3)(suppl 2):S32-S56
21 Summary Figures S32 Definitions DATA ANALYSES DIABETES Self-reported diabetes, self reported diabetic retinopathy, receiving medication for diabetes, or elevated blood glucose (WHO); fasting blood sugar
More informationKEEP 2009 Summary Figures
S4 29 Summary Figures American Journal of Kidney Diseases, Vol 55, No 3, Suppl 2, 21:pp S4-S57 S41 Definitions DATA ANALYSES DIABETES Self-reported diabetes, self reported diabetic retinopathy, receiving
More informationKEEP S u m m a r y F i g u r e s. American Journal of Kidney Diseases, Vol 53, No 4, Suppl 4, 2009:pp S32 S44.
28 S u m m a r y F i g u r e s American Journal of Kidney Diseases, Vol 53, No 4, Suppl 4, 29:pp S32 S44. S32 Definitions S33 Data Analyses Diabetes Self-reported diabetes, self reported diabetic retinopathy,
More informationEXECUTIVE SUMMARY S3. ONE Program Introduction S5. TWO Participant Characteristics S16. THREE Obesity & Body Mass Index S28
KEEP EXECUTIVE SUMMARY S3 ONE Program Introduction S5 TWO Participant Characteristics S16 THREE Obesity & Body Mass Index S28 FOUR Major Risk Factors for Chronic Kidney Disease S34 FIVE Chronic Kidney
More informationA n aly tical m e t h o d s
a A n aly tical m e t h o d s If I didn t go to the screening at Farmers Market I would not have known about my kidney problems. I am grateful to the whole staff. They were very professional. Thank you.
More informationAnalytical Methods: the Kidney Early Evaluation Program (KEEP) The Kidney Early Evaluation program (KEEP) is a free, community based health
Analytical Methods: the Kidney Early Evaluation Program (KEEP) 2000 2006 Database Design and Study Participants The Kidney Early Evaluation program (KEEP) is a free, community based health screening program
More informationS150 KEEP Analytical Methods. American Journal of Kidney Diseases, Vol 55, No 3, Suppl 2, 2010:pp S150-S153
S150 KEEP 2009 Analytical Methods American Journal of Kidney Diseases, Vol 55, No 3, Suppl 2, 2010:pp S150-S153 S151 The Kidney Early Evaluation program (KEEP) is a free, communitybased health screening
More informationKEEP 2005 Annual Data Report
KEEP 25 Annual Data Report The National Kidney Foundation gratefully acknowledges the support of our primary sponsor and our associate sponsor Additional thanks to Bayer Diagnostics, Satellite Healthcare,
More informationKnow Your Number Aggregate Report Single Analysis Compared to National Averages
Know Your Number Aggregate Report Single Analysis Compared to National s Client: Study Population: 2242 Population: 3,000 Date Range: 04/20/07-08/08/07 Version of Report: V6.2 Page 2 Study Population Demographics
More informationQUICK REFERENCE FOR HEALTHCARE PROVIDERS
KEY MESSAGES 1 SCREENING CRITERIA Screen: Patients with DM and/or hypertension at least yearly. Consider screening patients with: Age >65 years old Family history of stage 5 CKD or hereditary kidney disease
More informationChronic kidney disease (CKD) has received
Participant Follow-up in the Kidney Early Evaluation Program (KEEP) After Initial Detection Allan J. Collins, MD, FACP, 1,2 Suying Li, PhD, 1 Shu-Cheng Chen, MS, 1 and Joseph A. Vassalotti, MD 3,4 Background:
More informationChronic Kidney Disease
Chronic Kidney Disease Chronic Kidney Disease (CKD) Educational Objectives Outline Demographics Propose Strategies to slow progression and improve outcomes Plan for treatment of CKD Chronic Kidney Disease
More informationKidney Early Evaluation Program KEEP. A n n u a l D a t a R e p o r t
Kidney Early Evaluation Program KEEP A n n u a l D a t a R e p o r t The National Kidney Foundation gratefully acknowledges the support of our primary sponsor and our associate sponsors Additional thanks
More informationOutline. Outline 10/14/2014 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationRegional and Hispanic Subgroup Disparities in the Prevalence of Diabetes & Hypertension Among Older Adults
Regional and Hispanic Subgroup Disparities in the Prevalence of Diabetes & Hypertension Among Older Adults Catherine Pérez Jennifer A. Ailshire Conference Series on Aging in the Americas September 21,
More informationOutline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 7/23/2013. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationUpdate on HIV-Related Kidney Diseases. Agenda
Update on HIV-Related Kidney Diseases ANDY CHOI THE MEDICAL MANAGEMENT OF HIV/AIDS DECEMBER 15, 2006 Agenda 1. EPIDEMIOLOGY: A) END STAGE RENAL DISEASE (ESRD) B) CHRONIC KIDNEY DISEASE (CKD) 2. HIV-ASSOCIATED
More informationChapter Two Renal function measures in the adolescent NHANES population
0 Chapter Two Renal function measures in the adolescent NHANES population In youth acquire that which may restore the damage of old age; and if you are mindful that old age has wisdom for its food, you
More informationOutline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationChronic Kidney Disease is Associated with Cognitive Decline: the Northern Manhattan Study (NOMAS) Seattle VA Chief of Medicine Rounds June 9, 2009
Chronic Kidney Disease is Associated with Cognitive Decline: the Northern Manhattan Study (NOMAS) Seattle VA Chief of Medicine Rounds June 9, 2009 Minesh Khatri Internal Medicine R2 Background Patients
More informationPREVALENCE, RISK FACTORS, ADHERENCE AND NON ADHERENCE IN PATIENT WITH CHRONIC KIDNEY DISEASE: A PROSPECTIVE STUDY
INTERNATIONAL JOURNAL OF RESEARCH IN PHARMACY AND CHEMISTRY Available online at www.ijrpc.com Research Article PREVALENCE, RISK FACTORS, ADHERENCE AND NON ADHERENCE IN PATIENT WITH CHRONIC KIDNEY DISEASE:
More informationGuest Speaker Evaluations Viewer Call-In Thanks to our Sponsors: Phone: Fax: Public Health Live T 2 B 2
Public Health Live T 2 B 2 Chronic Kidney Disease in Diabetes: Early Identification and Intervention Guest Speaker Joseph Vassalotti, MD, FASN Chief Medical Officer National Kidney Foundation Thanks to
More informationThe Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009
The Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009 Teresa Northcutt, RN BSN Primaris Program Manager, Prevention - CKD MO-09-01-CKD This material was prepared by Primaris,
More informationAcknowledgements. National Kidney Foundation of Connecticut Mark Perazella. Co-PI Slowing the progression of chronic kidney disease to ESRD
A Practical Approach to Chronic Kidney Disease Management for the Primary Care Practioner: A web-site sponsored by the National Kidney Foundation of Connecticut Robert Reilly, M.D. Acknowledgements National
More informationPrimary Care Physicians and Clinicians. XXX on behalf of the Upper Midwest Fistula First Coalition. Chronic Kidney Disease (CKD) Resources
August 10, 2007 To: From: RE: Primary Care Physicians and Clinicians XXX on behalf of the Upper Midwest Fistula First Coalition Chronic Kidney Disease (CKD) Resources Caring for patients with chronic kidney
More informationLucia Cea Soriano 1, Saga Johansson 2, Bergur Stefansson 2 and Luis A García Rodríguez 1*
Cea Soriano et al. Cardiovascular Diabetology (2015) 14:38 DOI 10.1186/s12933-015-0204-5 CARDIO VASCULAR DIABETOLOGY ORIGINAL INVESTIGATION Open Access Cardiovascular events and all-cause mortality in
More informationRationale: Objectives: Indication: Diabetes Mellitus, Type 2 Study Investigators/Centers: 300 physicians in 292 clinics Research Methods: Data Source:
GSK Medicine: N/A Study No.: 112255 Title: A Korean, multi-center, nation-wide, cross-sectional, epidemiology study to identify prevalence of diabetic nephropathy in hypertensive patients with type 2 diabetes
More informationTREAT THE KIDNEY TO SAVE THE HEART. Leanna Tyshler, MD Chronic Kidney Disease Medical Advisor Northwest Kidney Centers February 2 nd, 2009
TREAT THE KIDNEY TO SAVE THE HEART Leanna Tyshler, MD Chronic Kidney Disease Medical Advisor Northwest Kidney Centers February 2 nd, 2009 1 ESRD Prevalent Rates in 1996 per million population December
More informationTrial to Reduce. Aranesp* Therapy. Cardiovascular Events with
Trial to Reduce Cardiovascular Events with Aranesp* Therapy John J.V. McMurray, Hajime Uno, Petr Jarolim, Akshay S. Desai, Dick de Zeeuw, Kai-Uwe Eckardt, Peter Ivanovich, Andrew S. Levey, Eldrin F. Lewis,
More informationScreening for chronic kidney disease racial implications. Not everybody that pees has healthy kidneys!
Screening for chronic kidney disease racial implications Not everybody that pees has healthy kidneys! Screening for chronic kidney disease racial implications 1) Definition of CKD 2) Why should we screen
More informationRenal function vs chemotherapy dosing
Renal function vs chemotherapy dosing Jenny Casanova Senior Clinical Pharmacist Repatriation General Hospital Daw Park 1 Methods of estimating renal function Cockcroft-Gault (1976) C-G using ideal vs actual
More informationCase Studies: Renal and Urologic Impairments Workshop
Case Studies: Renal and Urologic Impairments Workshop Justine Lee, MD, DBIM New York Life Insurance Co. Gina Guzman, MD, DBIM, FALU, ALMI Munich Re AAIM Triennial October, 2012 The Company You Keep 1 Case
More informationOutline. Outline. Introduction CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 8/11/2011
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationSection Questions Answers
Section Questions Answers Guide to CKD Screening and Evaluation -Alec Otteman, MD Delaying Progression - Paul Drawz, MD, MHS, MS 1. Modifiable risk factors for CKD include: a. Diabetes b. Hypertension
More informationpatient characteriuics Chapter Two introduction 58 increasing complexity of the patient population 60 epo use & anemia in the pre-esrd period 62
introduction 58 < increasing complexity of the patient population 6 < epo use & anemia in the pre-esrd period 62 < biochemical & physical characteristics at initiation 64 < estimated gfr at intiation &
More informationCKDinform: A PCP s Guide to CKD Detection and Delaying Progression
CKDinform: A PCP s Guide to CKD Detection and Delaying Progression Learning Objectives Describe suitable screening tools, such as GFR and ACR, for proper utilization in clinical practice related to the
More informationOutline. Introduction. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 6/26/2012
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationScreening and early recognition of CKD. John Ngigi (FISN) Kidney specialist
Screening and early recognition of CKD John Ngigi (FISN) Kidney specialist screening Why? Who? When? How? Primary diagnosis for patients who start dialysis Other 10% Glomerulonephritis 13% No. of dialysis
More informationWHEN (AND WHEN NOT) TO START DIALYSIS. Shahid Chandna, Ken Farrington
WHEN (AND WHEN NOT) TO START DIALYSIS Shahid Chandna, Ken Farrington Changing Perspectives Beta blockers 1980s Contraindicated in heart failure Now mainstay of therapy HRT 1990s must Now only if you have
More informationCharacteristics of factor x so that its clearance = GFR. Such factors that meet these criteria. Renal Tests. Renal Tests
Renal Tests Holly Kramer MD MPH Associate Professor of Public Health Sciences and Medicine Division of Nephrology and Hypertension Loyola University of Chicago Stritch School of Medicine Renal Tests 1.
More informationCHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationAddressing Chronic Kidney Disease in People with Multiple Chronic Conditions
Addressing Chronic Kidney Disease in People with Multiple Chronic Conditions Andrew S Narva, MD Na/onal Kidney Disease Educa/on Program U.S. Department of Health and Human Services National Institute of
More informationChronic Kidney Disease
Chronic Kidney Disease Presence of kidney damage or decreased kidney function for three or more months, - necessary to distinguish CKD from acute kidney disease. Ascertained either by kidney biopsy or
More informationChapter 1: CKD in the General Population
Chapter 1: CKD in the General Population Overall prevalence of CKD (Stages 1-5) in the U.S. adult general population was 14.8% in 2011-2014. CKD Stage 3 is the most prevalent (NHANES: Figure 1.2 and Table
More informationSurvey of U.S. Adult Cigarette Smokers
Survey of U.S. Adult Cigarette Smokers Topline Report 13 October 2016 ADULT CIGARETTE SMOKERS (U.S. NATIONWIDE): n=1,000 online surveys S1. First, which of the following ranges includes your age? 0% Under
More informationDisclosures. Outline. Outline 5/23/17 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationCKD FOR PRIMARY CARE MINNESOTA ACADEMY OF PHYSICIANS 2017 HEATHER ANN MUSTER, MD MS
CKD FOR PRIMARY CARE MINNESOTA ACADEMY OF PHYSICIANS 2017 HEATHER ANN MUSTER, MD MS PLoS One. 2014 Nov 26;9(11):e110535. Of the 445 PCPs who enrolled at least 10 patients, 19 (4.3%) had >50% likelihood
More informationDisclosures. Outline. Outline 7/27/2017 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationA New Approach for Evaluating Renal Function and Predicting Risk. William McClellan, MD, MPH Emory University Atlanta
A New Approach for Evaluating Renal Function and Predicting Risk William McClellan, MD, MPH Emory University Atlanta Goals Understand the limitations and uses of creatinine based measures of kidney function
More informationClinical Study Relationship between Plasma Leptin Level and Chronic Kidney Disease
International Nephrology Volume 2012, Article ID 269532, 6 pages doi:10.1155/2012/269532 Clinical Study Relationship between Plasma Leptin Level and Chronic Kidney Disease Anoop Shankar, 1 Shirmila Syamala,
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and
More informationmean hemoglobin 11 g/dl (110 g/l) compared to patients with lower mean hemoglobin values (Table 20).
S44 Figure 53 depicts the trend in Epoetin dosing from the 1998 study period to the 2003 study period, with an increasing mean weekly Epoetin dose (units/kg/wk) for patients prescribed Epoetin in lower
More informationCHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH SCIENTIFIC DIRECTOR KIDNEY HEALTH RESEARCH COLLABORATIVE - UCSF CHIEF - GENERAL INTERNAL MEDICINE, SAN FRANCISCO
More informationObjectives. Pre-dialysis CKD: The Problem. Pre-dialysis CKD: The Problem. Objectives
The Role of the Primary Physician and the Nephrologist in the Management of Chronic Kidney Disease () By Brian Young, M.D. Assistant Clinical Professor of Medicine David Geffen School of Medicine at UCLA
More informationCorrespondence should be addressed to Maisarah Jalalonmuhali;
Hindawi International Journal of Nephrology Volume 2017, Article ID 2901581, 7 pages https://doi.org/10.1155/2017/2901581 Research Article Comparative Performance of Creatinine-Based Estimated Glomerular
More informationThe incidence and prevalence of hypertension
Hypertension and CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES), 1999-2004 Madhav V. Rao, MD, 1 Yang Qiu, MS, 2 Changchun Wang, MS, 2 and George
More informationAntibiotics requiring dosage adjustment in community acquired pneumonia patients with renal impairment
1 Antibiotics requiring dosage adjustment in community acquired pneumonia patients with renal impairment Md Aslam Ali Hashmi 1, Meer Mudabbir Ali 1, MA Iqbal Rasheed 1, Syed Fawaz Hussain 1, Syed Areefulla
More informationThe estimation of kidney function with different formulas in overall population
137 G E R I A T R I A 213; 7: 137-141 Akademia Medycyny ARTYKUŁ ORYGINALNY/ORIGINAL PAPER Otrzymano/Submitted: 28.8.213 Zaakceptowano/Accepted: 2.9.213 The estimation of kidney function with different
More informationPredicting and changing the future for people with CKD
Predicting and changing the future for people with CKD I. David Weiner, M.D. Co-holder, C. Craig and Audrae Tisher Chair in Nephrology Professor of Medicine and Physiology and Functional Genomics University
More informationElevation of Serum Creatinine: When to Screen, When to Refer. Bruce F. Culleton, MD, FRCPC; and Jolanta Karpinski, MD, FRCPC
Elevation of Serum Creatinine: When to Screen, When to Refer Bruce F. Culleton, MD, FRCPC; and Jolanta Karpinski, MD, FRCPC Presented at the University of Calgary s CME and Professional Development 2006-2007
More informationDiabetic Kidney Disease in the Primary Care Clinic
Diabetic Kidney Disease in the Primary Care Clinic Jess Wheeler, DO Nephrology 2015 Outline: 1. CKD/DKD is a growing problem 2. Diagnosis of Chronic Kidney Disease (CKD) 3. Diagnosis of Diabetic Kidney
More information2017/3/7. Evaluation of GFR. Chronic Kidney Disease (CKD) Serum creatinine(scr) Learning Objectives
Evaluation of egfr and mgfr in CKD Use of CKD staging with case scenario Assessment of kidney function in CKD in adults Learning Objectives 台大雲林分院楊淑珍藥師 2017/03/11 Chronic Kidney Disease (CKD) Based on
More informationChronic Kidney Disease: Optimal and Coordinated Management
Chronic Kidney Disease: Optimal and Coordinated Management Michael Copland, MD, FRCPC Presented at University of British Columbia s 42nd Annual Post Graduate Review in Family Medicine Conference, Vancouver,
More informationMeasure Abbreviation: AKI 01 (QCDR Measure ID: ASPIRE19)
Measure Abbreviation: AKI 01 (QCDR Measure ID: ASPIRE19) Data Collection Method: This measure is calculated based on data extracted from the electronic medical record combined with administrative data
More informationRisk for chronic kidney disease increases with obesity: Health Survey for England 2010
Public Health Nutrition: 18(18), 3349 3354 doi:10.1017/s1368980015000488 Risk for chronic kidney disease increases with obesity: Health Survey for England 2010 Helen L MacLaughlin 1,2, *, Wendy L Hall
More informationDiabetes and Kidney Disease. Kris Bentley Renal Nurse practitioner 2018
Diabetes and Kidney Disease Kris Bentley Renal Nurse practitioner 2018 Aims Develop an understanding of Chronic Kidney Disease Understand how diabetes impacts on your kidneys Be able to recognise the risk
More informationRenal Function of Living Kidney Donors at Kenyatta National Hospital Nairobi-Kenya
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-853, p-issn: 2279-861.Volume 13, Issue 8 Ver. V (Aug. 214), PP 51-56 Renal Function of Living Kidney Donors at Kenyatta National Hospital
More informationGFR prediction using the MDRD and Cockcroft and Gault equations in patients with end-stage renal disease
Nephrol Dial Transplant (2005) 20: 2394 2401 doi:10.1093/ndt/gfi076 Advance Access publication 23 August 2005 Original Article GFR prediction using the MDRD and Cockcroft and Gault equations in patients
More informationCreatinine levels among Mexican Americans, Puerto Ricans, and Cuban Americans in the Hispanic Health and Nutrition Examination Survey
Kidney International, Vol. 66 (2004), pp. 2368 2373 Creatinine levels among Mexican Americans, Puerto Ricans, and Cuban Americans in the Hispanic Health and Nutrition Examination Survey RUDOLPH A. RODRIGUEZ,GERMAN
More informationThe impact of albuminuria and cardiovascular risk factors on renal function Verhave, Jacoba Catharijne
University of Groningen The impact of albuminuria and cardiovascular risk factors on renal function Verhave, Jacoba Catharijne IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's
More informationT. Suithichaiyakul Cardiomed Chula
T. Suithichaiyakul Cardiomed Chula The cardiovascular (CV) continuum: role of risk factors Endothelial Dysfunction Atherosclerosis and left ventricular hypertrophy Myocardial infarction & stroke Endothelial
More informationPopulation Percent C.I * 6.3% ± * 20.7% ± % ± * 54.2% ± and older * 59.3% ± 2.9.
Overview Why Is This Indicator Important? High cholesterol is one of the leading risk factor for heart disease and stroke, the1st and 3 rd leading causes of death in US. How Are We Doing? In 1, 32% Hennepin
More informationEpidemiology of CKD in Children
Epidemiology of CKD in Children Ali Düzova, M.D. Hacettepe University Faculty of Medicine Pediatric Nephrology and Rheumatology Unit Ankara CKD Course 03 June 2011, İstanbul Aim & Plan Causes of CKD in
More informationEgfr non african american vs african american
Buscar... Egfr non african american vs african american 15-2-2017 Chronic TEENney disease (CKD) is a condition characterized by a gradual loss of TEENney function over time. To read more about TEENney
More information8 th Annual Congress of the Bangladesh Society of Medicine Dhaka, Bangladesh March 23-24, Jeffrey P. Harris MD, FACP
8 th Annual Congress of the Bangladesh Society of Medicine Dhaka, Bangladesh March 23-24, 2008 The Internist and the Pre-End Stage Renal Disease Patient Jeffrey P. Harris MD, FACP Country: Bangladesh Population:
More informationAshberyh CHAPTER. John
A knowledge that people live close by is, I think, enough. And even if only first names are ever exchanged The people who own them seem rock-true and marvelously self-suficient. John Ashberyh The Ongoing
More informationKnow Your Number Aggregate Report Comparison Analysis Between Baseline & Follow-up
Know Your Number Aggregate Report Comparison Analysis Between Baseline & Follow-up... Study Population: 340... Total Population: 500... Time Window of Baseline: 09/01/13 to 12/20/13... Time Window of Follow-up:
More informationLessons learned from AASK (African-American Study of Kidney Disease and Hypertension)
Lessons learned from AASK (African-American Study of Kidney Disease and Hypertension) Janice P. Lea, MD, MSc, FASN Professor of Medicine Chief Medical Director of Emory Dialysis ASH Clinical Specialist
More informationLab Values Explained. working at full strength. Other possible causes of an elevated BUN include dehydration and heart failure.
Patient Education Lab Values Explained Common Tests to Help Diagnose Kidney Disease Lab work, urine samples and other tests may be given as you undergo diagnosis and treatment for renal failure. The test
More informationFREQUENTLY ASKED QUESTIONS ABOUT GFR ESTIMATES
FREQUENTLY ASKED QUESTIONS ABOUT GFR ESTIMATES TABLE OF CONTENTS MEASUREMENT OF KIDNEY FUNCTION 4 1) What is GFR? 4 2) How is GFR measured? 4 3) What does GFR indicate? 4 4) Why measure GFR as an index
More informationMorbidity & Mortality from Chronic Kidney Disease
Morbidity & Mortality from Chronic Kidney Disease Dr. Lam Man-Fai ( 林萬斐醫生 ) Honorary Clinical Assistant Professor MBBS, MRCP, FHKCP, FHKAM, PDipID (HK), FRCP (Edin, Glasg) Hong Kong Renal Registry Report
More informationHealth Outcomes in the SSHVS Population Study. Loretta R Cain, MPH, PhD The University of Chicago
Health Outcomes in the SSHVS Population Study Loretta R Cain, MPH, PhD The University of Chicago Background Objective measures to assess status of prevalent health conditions are needed to identify: Diagnosed
More informationDiabetes and Hypertension
Diabetes and Hypertension M.Nakhjvani,M.D Tehran University of Medical Sciences 20-8-96 Hypertension Common DM comorbidity Prevalence depends on diabetes type, age, BMI, ethnicity Major risk factor for
More informationegfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
More informationCystatin C: A New Approach to Improve Medication Dosing
Cystatin C: A New Approach to Improve Medication Dosing Erin Frazee Barreto, PharmD, MSc, FCCM Assistant Professor of Pharmacy and Medicine Kern Scholar, Center for the Science of Health Care Delivery
More informationChapter 2 Chronic Kidney Disease (CKD) in Cancer Patients
Chapter 2 Chronic Kidney Disease (CKD) in Cancer Patients Mala Sachdeva, Amit Lahoti and Anna Mathew List of Abbreviations ACE Angiotensin converting enzyme AKI Acute kidney injury ARB Angiotensin II receptor
More informationChronic Kidney Disease Prevalence and Rate of Diagnosis
The American Journal of Medicine (2007) 120, 981-986 CLINICAL RESEARCH STUDY Chronic Kidney Disease Prevalence and Rate of Diagnosis Timothy P. Ryan, PhD, a James A. Sloand, MD, b Paul C. Winters, MS,
More informationE.Ritz Heidelberg (Germany)
Predictive capacity of renal function in cardiovascular disease E.Ritz Heidelberg (Germany) If a cure is not achieved, the kidneys will pass on the disease to the heart Huang Ti Nei Ching Su Wen The Yellow
More informationThe organs of the human body were created to perform ten functions among which is the function of the kidney to furnish the human being with thought.
The organs of the human body were created to perform ten functions among which is the function of the kidney to furnish the human being with thought. Leviticus Rabba 3 Talmud Berochoth 6 1 b Outline &
More informationCHRONIC RENAL FAILURE: WHAT THE PRIMARY CARE CAN OFFER. The annual conference of the Lebanese Society of Family Medicine October 2017 Dr Hiba AZAR
CHRONIC RENAL FAILURE: WHAT THE PRIMARY CARE CAN OFFER The annual conference of the Lebanese Society of Family Medicine October 2017 Dr Hiba AZAR OUTLINE: A journey through CKD Screening for CKD: The why,
More informationTenofovir plasma exposures and Creatinine Clearance changes in 1st line Regimen of African patients in Cameroon and Senegal: ANRS12115 DAYANA study
Abstract O_03 Tenofovir plasma exposures and Creatinine Clearance changes in 1st line Regimen of African patients in Cameroon and Senegal: ANRS12115 DAYANA study M.P. Lê Pharmacy Resident Clinical Pharmacology
More informationTwo: Chronic kidney disease identified in the claims data. Chapter
Two: Chronic kidney disease identified in the claims data Though leaves are many, the root is one; Through all the lying days of my youth swayed my leaves and flowers in the sun; Now may wither into the
More informationCareer Corner: Pharmaceutical Calculations for Technicians. Ashlee Mattingly, PharmD, BCPS
Career Corner: Pharmaceutical Calculations for Technicians Ashlee Mattingly, PharmD, BCPS Disclosure I have no actual or potential conflict(s) of interest in relation to this program. Learning Objectives
More informationchanges that occur in kidney with aging is THE MOST DRAMATIC ANY ORGAN SYSTEM.
The Kidney in Aging The the OF OF changes that occur in kidney with aging is THE MOST DRAMATIC ANY ORGAN SYSTEM. Age related charges in kidney structure and function At age 2 GFR at adult level. Reamins
More informationIs CKD prevalence of 10-13% in Europe, US and China a realistic number or is there overdiagnosis of CKD? Marc E De Broe.
Is CKD prevalence of 10-13% in Europe, US and China a realistic number or is there overdiagnosis of CKD? Marc E De Broe November 2016 An example of partnership Maremar Maladies rénales au Maroc CKD IN
More informationDisclosures. Topics. Staging and GFR. K-DOQI Staging of Chronic Kidney Disease. Definition of Chronic Kidney Disease. Chronic Kidney Disease
Disclosures Chronic Kidney Disease Consultant: Baxter Healthcare J. Kevin Tucker, M.D. Brigham and Women s Hospital Massachusetts General Hospital Topics Staging of chronic kidney disease (CKD) How to
More informationKDIGO conference on high CV risk associated with CKD. The role of BP in CKD stage 1-4
KDIGO conference on high CV risk associated with CKD The role of BP in CKD stage 1-4 Johannes Mann, MD & Catherine Clase, MB BChir Friedrich Alexander University, Erlangen-Nuremberg Munich General Hospitals,
More information